Environmental enrichment and cerebrolysin improve motor and cognitive performance in a rat model of stroke, in conjunction with an increase in hippocampal AMPA but not NMDA receptor subunits.

Martínez-Torres NI, Cárdenas-Bedoya J, Vázquez-Torres BM, Torres-Mendoza BM

Brain research2 Dec 2023Cited by 3 (Europe PMC)

PMID38048977DOI10.1016/j.brainres.2023.148694PepBankPUB-38048977

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In stroke model rats, infarct size decreased in all treated groups, including cerebrolysin alone.
In plain wordsIn rats with stroke, infarct size decreased in all treated groups, including cerebrolysin alone.
Peptide
Cerebrolysin
Outcome
DecreaseInfarct size with cerebrolysin alone
Study
ratn: not reported in source
Male rats with induced stroke
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
2.5 ml/kg · 10 daysAs given in this study (rat).
Source sentences
Summary
Moreover, the infarct size decreased in all the groups that received a treatment, but an increase occurred in AMPA-GRIA1 only in experimental group regarding to control group, while NMDA-R1 had no differences.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, stroke was induced in 40 male rats and 24 h later, they were administered cerebrolysin (2.5 ml/kg), put in an environmentally enriched arena or given both treatments, for 10 days.
Report a problemFND-3804897703

Studies that did not test the peptide alone5

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

02AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In stroke model rats, cerebrolysin and environmental enrichment enhanced motor recovery, without a stated separation of treatment effects.
In plain wordsIn rats with stroke, cerebrolysin and environmental enrichment enhanced motor recovery without separate treatment effects.
Peptide
Cerebrolysin
Outcome
IncreaseMotor performance
Study
ratn: not reported in source
Male rats with induced stroke
Outcome group
Exercise and physical function · Nervous system and cognition
Source sentences
Summary
In motor and cognitive performance, the administration of cerebrolysin and environmental enrichment enhanced recovery.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, stroke was induced in 40 male rats and 24 h later, they were administered cerebrolysin (2.5 ml/kg), put in an environmentally enriched arena or given both treatments, for 10 days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3804897701
03AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In stroke model rats, cerebrolysin and environmental enrichment enhanced cognitive recovery, without a stated separation of treatment effects.
In plain wordsIn rats with stroke, cerebrolysin and environmental enrichment enhanced cognitive recovery without separate treatment effects.
Peptide
Cerebrolysin
Outcome
IncreaseCognitive performance
Study
ratn: not reported in source
Male rats with induced stroke
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
In motor and cognitive performance, the administration of cerebrolysin and environmental enrichment enhanced recovery.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, stroke was induced in 40 male rats and 24 h later, they were administered cerebrolysin (2.5 ml/kg), put in an environmentally enriched arena or given both treatments, for 10 days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3804897702
04AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In stroke model rats, infarct size decreased in all treated groups, including cerebrolysin with environmental enrichment.
In plain wordsIn rats with stroke, infarct size decreased in all treated groups, including cerebrolysin with environmental enrichment.
Peptide
Cerebrolysin
Outcome
DecreaseInfarct size with combined treatment
Study
ratn: not reported in source
Male rats with induced stroke
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Moreover, the infarct size decreased in all the groups that received a treatment, but an increase occurred in AMPA-GRIA1 only in experimental group regarding to control group, while NMDA-R1 had no differences.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, stroke was induced in 40 male rats and 24 h later, they were administered cerebrolysin (2.5 ml/kg), put in an environmentally enriched arena or given both treatments, for 10 days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3804897704
05AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism
In stroke model rats, AMPA-GRIA1 increased only in the experimental group compared with controls in the cerebrolysin/environmental enrichment study.
In plain wordsIn rats with stroke, AMPA-GRIA1 increased only in the experimental group compared with controls.
Peptide
Cerebrolysin
Outcome
IncreaseHippocampal AMPA-GRIA1
Study
ratn: not reported in source
Male rats with induced stroke
Comparator
Control group
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, the infarct size decreased in all the groups that received a treatment, but an increase occurred in AMPA-GRIA1 only in experimental group regarding to control group, while NMDA-R1 had no differences.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, stroke was induced in 40 male rats and 24 h later, they were administered cerebrolysin (2.5 ml/kg), put in an environmentally enriched arena or given both treatments, for 10 days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3804897705
06AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism
In stroke model rats, the cerebrolysin/environmental enrichment study reported no differences in NMDA-R1.
In plain wordsIn rats with stroke, the cerebrolysin and environmental enrichment study found no differences in NMDA-R1.
Peptide
Cerebrolysin
Outcome
No significant changeHippocampal NMDA-R1
Study
ratn: not reported in source
Male rats with induced stroke
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, the infarct size decreased in all the groups that received a treatment, but an increase occurred in AMPA-GRIA1 only in experimental group regarding to control group, while NMDA-R1 had no differences.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, stroke was induced in 40 male rats and 24 h later, they were administered cerebrolysin (2.5 ml/kg), put in an environmentally enriched arena or given both treatments, for 10 days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3804897706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.